GOLDMAN STEVEN A has a total of 11 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 1999. It filed its patents most often in United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CARITAS ST ELIZABETH MEDICAL C, TOKYOTO IGAKU KENKYU KIKO and FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE NAUCHNOE UCHREZHDENIE NAUCHNO ISSLEDOVATELSKIJ INST VAKTSIN I.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Environmental technology | |
#5 | Agriculture |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Therapeutic chemical compounds | |
#5 | Climate change adaptation technologies | |
#6 | Animal care | |
#7 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Goldman Steven A | 11 |
#2 | Roy Neeta Singh | 5 |
#3 | Nakano Takahiro | 2 |
#4 | Windrem Martha | 2 |
#5 | Auvergne Romane | 1 |
#6 | Wang Su | 1 |
#7 | Sim Fraser | 1 |
Publication | Filing date | Title |
---|---|---|
US2016317681A1 | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder | |
US8524499B2 | Regulatory sequences that direct gene expression to spinal motor neurons and uses thereof | |
US8263406B2 | Enriched or purified population of motor neurons and its preparation from a population of embryonic stem cells | |
US8642332B2 | Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain | |
US2004029269A1 | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells | |
US8263402B1 | Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells |